Publikationen

2020

Originalarbeiten

Kriegsmann K, Hundemer M, Hofmeister-Mielke N, Reichert P, Manta CP, Awwad MHS, Sauer S, Bertsch U, Besemer B, Fenk R, Hänel M, Munder M, Weisel KC, Blau IW, Neubauer A, Müller-Tidow C, Raab MS, Goldschmidt H, Huhn S, German-speaking Myeloma Multicenter Group (GMMG): Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment. Cancers 2020, 12(8): E2322.

Goldschmidt H, Baertsch MA, Schlenzka J, Becker N, Habermehl C, Hielscher T, Raab MS, Hillengass J, Sauer S, Müller-Tidow C, Luntz S, Jauch A, Hose D, Seckinger A, Brossart P, Goerner M, Klein S, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Haenel M, Martin H, Lindemann HW, Scheid C, Nogai A, Salwender H, Noppeney R, Besemer B, Weisel K, German-speaking Myeloma Multicenter Group: Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia 2020.

Mai EK, Miah K, Bertsch U, Dürig J, Scheid C, Weisel KC, Kunz C, Munder M, Lindemann HW, Merz M, Hose D, Jauch A, Seckinger A, Luntz S, Sauer S, Fuhrmann S, Brossart P, Elmaagacli A, Goerner M, Bernhard H, Hoffmann M, Raab MS, Blau IW, Hänel M, Benner A, Salwender HJ, Goldschmidt H, German-speaking Myeloma Multicenter Group:  Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. Leukemia 2020.

Goldschmidt H, Mai EK, Duerig J, Scheid C, Weisel KC, Kunz C, Bertsch U, Hielscher T, Merz M, Munder M, Lindemann HW, Huegle-Doerr B, Tichy D, Giesen N, Hose D, Seckinger A, Huhn S, Luntz S, Jauch A, Elmaagacli A, Rabold B, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Hoffmann M, Hillengass J, Raab MS, Blau IW, Haenel M, Salwender HJ, German-speaking Myeloma Multicenter Group: Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia 2020, 34(7):1853 – 1865. 

Knauf W, Dingeldein G, Schlag R, Welslau M, Moehler T, Terzer T, Walter S, Habermehl C, Kunz C, Goldschmidt H, Raab MS, BPV trial group: First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients. European journal of haematology 2020, 105(2):116-125.

Kongressbeiträge

Raab MS, Giesen N, Scheid C, Besemer B, Miah K, Benner A, v. Metzler I, Khandanpour C, Seidel-Glaetzer A, Trautmann-Grill K, Mechtersheimer G, Goeppert B, Stenzinger A, Goldschmidt H, Weisel K, Chatterjee M: Safety and Preliminary Efficacy Results from a Phase II Study Evaluating Combined BRAF and MEK Inhibition in Relapsed/Refractory Multiple Myeloma (rrMM) Patients with Activating BRAF V600E Mutations: the GMMG-BIRMA Trial. 62nd ASH Annual Meeting 2020 (5.-8.Dez. 2020)

Weisel K, Asemissen AM, Besemer B, Haenel M, Blau IW, Goerner M, Ko Y-D, Duerig J, Staib P, Mann C, Lutz R, Munder M, Graeven U, Peceny R, Salwender H, Zago M, Benner A, Tichy D, Bokemeyer C, Goldschmidt H: Depth of response to isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: Interim analysis of the GMMG-CONCEPT trial. In.: American Society of Clinical Oncology; 2020.

Kriegsmann K, Hundemer M, Hofmeister-Mielke N, Reichert P, Manta C-P, Awwad MH, Sauer S, Bertsch U, Kriegsmann M, Besemer B, Fenk R, Haenel M, Munder M, Weisel K, Blau IW, Mueller-Tidow C, Raab MS, Goldschmidt H: Comparison of next generation sequencing and next generation flow key metrics in multiple myeloma MRD assessment: Data from the GMMG HD6 trial: EP943. HemaSphere 2020, 4:S1:426-427.

Goldschmidt H, Mai EK, Salwender H, Bertsch U, Miah K, Kunz C, Fenk R, Blau IW, Scheid C, Martin H, Thomalla J, Mahlberg R, Raab M, Huhn S, Hose D, Jauch A, Graeven U, Wattad M, Besemer B, Seidel-Glaetzer A, Schroers R, Neubauer A, Duerig J, Munder M, Haenel M, Weisel K: Bortezomib, lenalidomide and dexamethasone with or without elotuzumab as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma: S203. HemaSphere 2020, 4:S1:58-58.

Asemissen AM, Scheid C, Leypoldt L, Schieferdecker A, Besemer B, Blau IW, Goerner M, Ko Y-D, Haenel M, Staib P, Salwender H, Mann C, Munder M, Graeven U, Peceny R, Lutz R, Zago M, Benner A, Tichy D, Bokemeyer C, Goldschmidt H, Weisel K: Mobilization of autologous stem cells under induction therapy with isatuximab, carfilzomib, lenalidomide, dexamethasone (ISA-KRD) in high-risk myeloma patients: first results of the GMMG-CONCEPT trial: EP987. HemaSphere 2020, 4:S1:451-451.

Weisel K, Asemissen AM, Besemer B, Haenel M, Blau IW, Goerner M, Ko Y-D, Duerig J, Staib P, Mann C, Lutz R, Munder M, Graeven U, Peceny R, Salwender H, Zago M, Benner A, Tichy D, Bokemeyer C, Goldschmidt H: Depth of response to isatuximab, carfilzomib, lenalidomide and dexamethasone (ISA-KRD) in frontline treatment of high-risk multiple myeloma: S204. HemaSphere 2020, 4:S1:58-59.

2019

Originalarbeiten

Weisel KC, Scheid C, Zago M, Besemer B, Mai EK, Haenel M, Duerig J, Munder M, Lindemann HW, Seckinger A, Kunz C, Benner A, Hose D, Jauch A, Salwender H, Goldschmidt H: Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial. Blood cancer journal 2019, 9(4):45.

Salwender H, Bertsch U, Weisel K, Duerig J, Kunz C, Benner A, Blau IW, Raab MS, Hillengass J, Hose D, Huhn S, Hundemer M, Andrulis M, Jauch A, Seidel-Glaetzer A, Lindemann HW, Hensel M, Fronhoffs S, Martens U, Hansen T, Wattad M, Graeven U, Munder M, Fenk R, Haenel M, Scheid C, Goldschmidt H: Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma. BMC cancer 2019, 19(1):504.

Merz M, Hielscher T, Mai EK, Seckinger A, Hose D, Jauch A, Sauer S, Luntz S, Bertsch U, Raab MS, Neben K, Salwender H, Blau IW, Lindemann HW, Duerig J, Scheid C, Haenel M, Weisel K, Weber T, Delorme S, Goldschmidt H, Hillengass J: Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma. Blood cancer journal 2019, 9(9):71.

Mai EK, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Gerecke C, Duehrsen U, Brossart P, Neben K, Hillengass J, Raab MS, Merz M, Baertsch MA, Jauch A, Hose D, Martin H, Lindemann HW, Blau IW, Scheid C, Weisel KC, Goldschmidt H, German-speaking Myeloma Multicenter G: Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma. Leukemia 2019, 33(1):258-261.

Kriegsmann K, Baertsch MA, Awwad MHS, Merz M, Hose D, Seckinger A, Jauch A, Becker N, Benner A, Raab MS, Hillengass J, Bertsch U, Duerig J, Salwender HJ, Haenel M, Fenk R, Munder M, Weisel K, Mueller-Tidow C, Goldschmidt H, Hundemer M: Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients. Blood cancer journal 2019, 9(2):13.

Hose D, Beck S, Salwender H, Emde M, Bertsch U, Kunz C, Scheid C, Haenel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Moreaux J, Seckinger A: Prospective target assessment and multimodal prediction of survival for personalized and risk-adapted treatment strategies in multiple myeloma in the GMMG-MM5 multicenter trial. Journal of hematology & oncology 2019, 12(1):65.

Kongressbeiträge

Weisel K, Asemissen AM, Schieferdecker A, Besemer B, Zago M, Mann C, Lutz R, Benner A, Tichy D, Bokemeyer C, Goldschmidt H: Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in front-line treatment of high-risk Multiple Myeloma: Results of the Safety Run-In cohort in the phase II, multicenter GMMG-CONCEPT trial. Clinical Lymphoma, Myeloma and Leukemia 2019, 19(10):e17.

Sonneveld P, Dejoie T, Zweegman S, Merz M, Weisel K, Lam A, Krotneva S, Proskorovsky I, Kampfenkel T, de Boer C, Cote S, Moreau P: A Matching-adjusted Indirect Comparison (MAIC) of Bortezomib-Thalidomide-Dexamethasone (VTd) and Daratumumab Plus VTd (D-VTd) Versus Bortezomib-Cyclophosphamide-Dexamethasone (VCd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) who are Transplant Eligible (TE). Clinical Lymphoma, Myeloma and Leukemia 2019, 19(10):e201-e202.

Scheid C, Lokhorst H, Blau IW, Van Der Holt B, Bertsch U, Zweegman S, Weisel K, Vellenga E, Kersten MJ, Croockewit S, Mai EK, Raymakers R, Hose D, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Neben K, Stilgenbauer S, Broyl A, Lindemann H-W, Bos G, Brossart P, van Marwijk Kooij M, Ypma PF, Duehrsen U, Schaafsma R, Hielscher T, Salwender H, Goldschmidt H, Sonneveld P: Bortezomib-Based Induction and Maintenance Overcomes the Negative Prognostic Impact of Renal Impairment and del17p in Transplant-Eligible Myeloma Patients: Long Term Results from the Phase III HOVON-65/GMMG-HD4 Study after Median 137 Months Follow up. Blood 2019, 134(Supplement_1):3308-3308.

Mai EK, Baertsch M-A, Hielscher T, Bertsch U, Schlenzka J, Salwender HJ, Munder M, Fuhrmann S, Duehrsen U, Brossart P, Neben K, Raab MS, Jauch A, Seckinger A, Hose D, Luntz S, Sonneveld P, Lokhorst H, Martin H, Lindemann H-W, Blau IW, Scheid C, Weisel K, Haenel M, Duerig J, Goldschmidt H: Comparison of bortezomib versus lenalidomide maintenance therapy in newly-diagnosed, transplant-eligible multiple myeloma: Results from the phase III GMMG-HD4 and-MM5 trials. Clinical Lymphoma, Myeloma and Leukemia 2019, 19(10):e43.

Mai E, Miah K, Merz M, Duerig J, Scheid C, Weisel K, Kunz C, Bertsch U, Munder M, Lindemann H-W, Hose D, Jauch A, Seckinger A, Luntz S, Sauer S, Furhmann S, Brossart P, Elmaagacli A, Goerner M, Bernhard H, Hoffmann M, Raab MS, Blau IW, Haenel M, Benner A, Salwender H, Goldschmidt H: High dose melphalan (200mg/m²) and autologous transplantation in newly-diagnosed multiple myeloma up to the age of 70 years: A subgroup analysis form the phase III GMMG-MM5 trial: PF597. HemaSphere 2019, 3:251-252.

Haas E-M, Salwender HJ, Mai EK, Duerig J, Weisel K, Tichy D, Benner A, Kunz C, Hielscher T, Bertsch U, Besemer B, Merz M, Munder M, Lindemann H-W, Huegle-Doerr B, Giessen N, Hose D, Seckinger A, Huhn S, Luntz S, Jauch A, Elmaagacli A, Rabold B, Fuhrmann S, Brossart P, Goerner M, Bernhard H, Hoffmann M, Hillengass J, Raab MS, Blau IW, Haenel M, Scheid C, Goldschmidt H: Normalization of serum free light chains during therapy in the MM5 trial predicts prolonged progression free survival and overall survival. Clinical Lymphoma, Myeloma and Leukemia 2019, 19(10):e208.

Chattopadhyay S, Thomsen H, Yadav P, da Silva Filho MI, Weinhold N, Nothen MM, Hoffman P, Bertsch U, Huhn S, Morgan GJ, Goldschmidt H, Houlston R, Hemminki K, Foersti A: Genome-wide interaction and pathway-based identification of key regulators in multiple myeloma. Communications biology 2019, 2(1):89.

Baertsch M-A, Schlenzka J, Hielscher T, Raab MS, Hillengass J, Mueller-Tidow C, Luntz S, Jauch A, Hose D, Seckinger A, Brossart P, Goerner M, Klein S, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Haenel M, Martin H, Lindemann H-W, Scheid C, Nogai A, Salwender H, Noppeney R, Weisel K, Goldschmidt H: Impact of cytogenetics at relapse on prognosis and benefit from salvage autologous stem cell transplantation in the GMMG phase III trial ReLApsE. Clinical Lymphoma, Myeloma and Leukemia 2019, 19(10):e286-e287.

Asemissen AM, Autenrieth S, Bieber K, Gouttefangeas C, Rammensee H-G, Besemer B, Mann C, Blau IW, Schieferdecker A, Bokemeyer C, Goldschmidt H, Weisel K: Prospective monitoring of immune signatures in newly diagnosed high risk multiple myeloma patients under treatment with Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd): First results of the GMMG-CONCEPT trial. Clinical Lymphoma, Myeloma and Leukemia 2019, 19(10):e141-e142.

 

2018

Originalarbeiten

Merz M, Jauch A, Hielscher T, Bochtler T, Schoenland SO, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Hillengass J, Salwender H, Blau IW, Lindemann H-W, Schmidt-Wolf IGH, Scheid C, Haenel M, Weisel KC, Goldschmidt H: Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma. Blood advances 2018, 2(1):1-9.

Goldschmidt H, Lokhorst HM, Mai EK, van der Holt B, Blau IW, Zweegman S, Weisel KC, Vellenga E, Pfreundschuh M, Kersten MJ, Scheid C, Croockewit S, Raymakers R, Hose D, Potamianou A, Jauch A, Hillengass J, Stevens-Kroef M, Raab MS, Broijl A, Lindemann HW, Bos GMJ, Brossart P, van Marwijk Kooy M, Ypma P, Duehrsen U, Schaafsma RM, Bertsch U, Hielscher T, Jarari L, Salwender HJ, Sonneveld P: Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia 2018, 32(2):383-390.

Kongressbeiträge

Weisel K, Salwender H, Scheid C, Zago M, Besemer B, Haenel M, Duerig J, Munder M, Lindemann H-W, Seckinger A, Kunz C, Benner A, Hose D, Jauch A, Kanz L, Goldschmidt H: Pomalidomide, cyclophosphamide and dexamethasone in case of suboptimal response to pomalidomide and dexamethasone alone in relapsed and/or refractory multiple myeloma: Final results of the GMMG-PERSPECTIVE trial. In: ONCOLOGY RESEARCH AND TREATMENT: 2018. KARGER: 133-134.

Seckinger A, Salwender HJ, Martin H, Scheid C, Hielscher T, Bertsch U, Hummel M, Jauch A, Knauf W, Emde M, Beck S, Neben K, Lokhorst HM, van der Holt B, Duehrsen U, Duerig J, Lindemann H-W, Schmidt-Wolf I, Haenel M, Lathan B, Raab MS, Mueller-Tidow C, Sonneveld P, Blau IW, Hillengass J, Weisel K, Goldschmdit H, Hose D: Treatment Response and Long-Term Survival in Multiple Myeloma in the GMMG-HD4 Trial-Neither Profit All Molecular Entities Alike, Nor Are Remissions to Different Regimen Equal. Blood 2018, 132(Supplement 1):4485-4485.

Sauer S, Sachpekidis C, Brandelik S, Spira D, Huhn S, Wagner B, Hummel M, Dimitrakopoulou-Strauss A, Mosebach J, Delorme S, Goldschmidt H, Mueller-Tidow C, Hillengass J: Prospective Evaluation of 18-F FDG PET/CT and Biopsies of Osteolytic Lesions and Random Bone Marrow Samples in Newly Diagnosed Multiple Myeloma Patients. Blood 2018, 132(Supplement 1):3180-3180.

Merz M, Hielscher T, Seckinger A, Jauch A, Mai E, Bertsch U, Raab MS, Neben K, Salwender H, Blau IW, Lindemann HW, Duerig J, Scheid C, Haenel M, Weisel K, Delorme S, Kauczor HU, Hose D, Goldschmidt H, Hillengass J: Prognostic significance of magnetic resonance imaging before and after upfront autologous transplantation for newly diagnosed multiple myeloma: a subgroup analysis from the GMMG MM5 phase III trial. In: 23rd Congress of EHA: 2018.

Knauf W, Dingeldein G, Schlag R, Welslau M, Kunz C, Moehler T, Habermehl C, Goldschmidt H, Raab MS, BPV-trial group: First-line therapy with Bendamustine/Prednisone/Bortezomib (BPV) for non-transplant eligible symptomatic multiple myeloma patients. In: ONCOLOGY RESEARCH AND TREATMENT: 2018. KARGER: 188-188.

Goldschmidt H, Baertsch M-A, Schlenzka J, Becker N, Christina H, Hielscher T, Raab MS, Hillengass J, Mueller-Tidow C, Luntz S, Jauch A, Brossart P, Goerner M, Klein S, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Haenel M, Martin H, Lindemann H-W, Scheid C, Nogai A, Salwender H, Noppeney R, Weisel K: Salvage autologous transplant and lenalidomide maintenance versus continuous lenalidomide/dexamethasone for relapsed multiple myeloma: results of the randomized GMMG phase III multicenter trial relapse. Blood 2018, 132(Supplement 1):253-253.

Baertsch M-A, Schlenzka J, Christina H, Hielscher T, Raab MS, Hillengass J, Mueller-Tidow C, Luntz S, Jauch A, Brossart P, Goerner M, Klein S, Schmidt-Hieber M, Reimer P, Graeven U, Fenk R, Haenel M, Martin H, Lindemann H-W, Scheid C, Nogai A, Salwender H, Noppeney R, Weisel K, Goldschmidt H: Subgroup analyses of the randomized GMMG phase III multicenter trial relapse suggest survival benefit of salvage autologous transplant primarily in low risk multiple myeloma. Blood 2018, 132(Supplement 1):254-254.

 

2017

Originalarbeiten

Schmitt M, Huckelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Haenel M, Weisel K, Bertsch U, Duerig J, Ho AD, Blau IW, Goldschmidt H, Seckinger A, Hose D: Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. Oncotarget 2017, 8(49):84847-84862.

Merz M, Jauch A, Hielscher T, Mai EK, Seckinger A, Hose D, Bertsch U, Neben K, Raab MS, Salwender H, Blau IW, Lindemann HW, Schmidt-Wolf I, Scheid C, Haenel M, Weisel K, Goldschmidt H, Hillengass J: Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. Haematologica 2017, 102(8):1432-1438.

Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, Bertsch U, Huegle-Doerr B, Vogel M, Angermund R, Haenel M, Salwender HJ, Weisel K, Duerig J, Goerner M, Kirchner H, Peter N, Graeven U, Lordick F, Hoffmann M, Reimer P, Blau IW, Jauch A, Dembowsky K, Moehler T, Wuchter P, Goldschmidt H: Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial. Bone marrow transplantation 2017, 52(8):1194-1198.

GroΔ JP, Nattenmüller J, Hemmer S, Tichy D, Krzykalla J, Goldschmidt H, Bertsch U, Delorme S, Kauczor H-U, Hillengass J, Merz M: Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma–subgroup analysis of the prospective GMMG MM5 trial. Oncotarget 2017, 8(40):68460.

Baertsch MA, Schlenzka J, Lisenko K, Krzykalla J, Becker N, Weisel K, Noppeney R, Martin H, Lindemann HW, Haenel M, Nogai A, Scheid C, Salwender H, Fenk R, Graeven U, Reimer P, Schmidt-Hieber M, Goerner M, Schmidt-Wolf IGH, Klein S, Ho AD, Goldschmidt H, Wuchter P: Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE. European journal of haematology 2017, 99(1):42-50.

Kongressbeiträge

Scheid C, Seckinger A, Duerig J, Weisel KC, Kunz C, Bertsch U, Hielscher T, Munder M, Lindemann H-W, Huegle-Doerr B, Huhn S, Mai EK, Jauch A, Rabold B, Gerecke C, Brossart P, Goerner M, Bernhard H, Hoffmann M, Hillengass J, Raab MS, Blau IW, Haenel M, Hose D, Goldschmidt H, Salwender H: Direct Assessment of IgA and IgG Paraprotein By Hevylite Assay and Correlation to IMWG Response and Progression-Free Survival in Newly Diagnosed, Transplant-Eligible Multiple Myeloma Patients in the Prospective Phase III GMMG-MM5 Trial. Blood 2017, 130(Supplement 1):1784-1784.

Huhn S, Haenel M, Hielscher T, Bertsch U, Salwender HJ, Peter N, Kirchner H, Bernhard H, Vogel M, Angermund R, Goerner M, Weisel K, Duering J, Blau IW, Weinhold N, Goldschmidt H: Circulating Tumor Cells As a Surrogate Marker for Bone Marrow Minimal Residual Disease and an Adverse Prognostic Factor for Patients with Multiple Myelom. Blood 2017, 130(Supplement 1):4359-4359.

Goldschmidt H, Mai EK, Duerig J, Scheid C, Weisel KC, Kunz C, Bertsch U, Hielscher T, Munder M, Lindemann H-W, Huegle-Doerr B, Hose D, Seckinger A, Huhn S, Jauch A, Rabold B, Elmaagacli A, Gerecke C, Brossart P, Goerner M, Bernhard H, Hoffmann M, Hillengass J, Raab MS, Blau IW, Haenel M, Salwender H: Response-adapted lenalidomide maintenance in newly diagnosed, transplant-eligible multiple myeloma: results from the multicenter phase III GMMG-MM5 trial. Blood 2017, 130(Supplement 1):400-400.

2016

Originalarbeiten

Weinhold N, Kirn D, Seckinger A, Hielscher T, Granzow M, Bertsch U, Egerer G, Salwender H, Blau IW, Weisel K, Hillengass J, Raab MS, Hose D, Goldschmidt H, Jauch A: Concomitant gain of 1q21 and MYC translocation define a poor prognostic subgroup of hyperdiploid multiple myeloma. Haematologica 2016, 101(3):e116-119.

Merz M, Salwender H, Haenel M, Mai EK, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Hose D, Seckinger A, Jauch A, Hillengass J, Raab MS, Schurich B, Munder M, Brossart P, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H: Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. Haematologica 2016, 101(12):e485-e487.

Mai EK, Benner A, Bertsch U, Brossart P, Haenel A, Kunzmann V, Naumann R, Neben K, Egerer G, Ho AD, Hillengass J, Raab MS, Neubauer A, Peyn A, Ko YD, Peter N, Scheid C, Goldschmidt H: Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial. British journal of haematology 2016, 173(5):731-741.

Kraemer I, Engelhardt M, Fichtner S, Neuber B, Medenhoff S, Bertsch U, Hillengass J, Raab MS, Hose D, Ho AD, Goldschmidt H, Hundemer M: Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro. Oncoimmunology 2016, 5(5):e1139662.

Kongressbeiträge

Wuchter P, Bertsch U, Salwender H-J, Munder M, Haenel M, Benner A, Becker N, Fenk R, Duerig J, Blau IW, Lisenko K, Hillengass J, Raab MS, Baertsch MA, Seidel-Glaetzer A, Ho AD, Graeven U, Scheid C, Weisel K, Goldschmidt H: Evaluation of stem cell mobilization in patients with multiple myeloma after lenalidomide-based induction chemotherapy within the GMMG-HD6 trial. In.: American Society of Hematology Washington, DC; 2016.

2015

Originalarbeiten

Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H: Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia 2015, 29(8):1721-1729.

Meißner T, Seckinger A, Hemminki K, Bertsch U, Foersti A, Haenel M, Duering J, Salwender H, Goldschmidt H, Morgan GJ, Hose D, Weinhold N: Profound impact of sample processing delay on gene expression of multiple myeloma plasma cells. BMC medical genomics 2015, 8:85.

Kuiper R, van Duin M, van Vliet MH, Broijl A, van der Holt B, El Jarari L, van Beers EH, Mulligan G, Avet-Loiseau H, Gregory WM, Morgan G, Goldschmidt H, Lokhorst HM, Sonneveld P: Prediction of high- and low-risk multiple myeloma based on gene expression and the International Staging System. Blood 2015, 126(17):1996-2004.

Kongressbeiträge

Merz M, Salwender H-J, Haenel M, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Mai EK, Hose D, Schurich B, Munder M, Brossart P, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H: Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma. In.: American Society of Hematology Washington, DC; 2015.

Mai EK, Kunz C, Bertsch U, Salwender H-J, Pfreundschuh M, Duehrsen U, Brossart P, Peter N, Neben K, Hielscher T, Hillengass J, Martin H, Lindemann HW, Scheid C, Weisel K, Blau IW, Goldschmidt H: Impact of Severe Infections during Induction Therapy on Dosage, Response and Survival in Newly Diagnosed Multiple Myeloma-a Subgroup Analysis from the Randomized Phase III Trial GMMG-HD4. In.: American Society of Hematology Washington, DC; 2015.

2014

Originalarbeiten

Scheid C, Sonneveld P, Schmidt-Wolf IG, van der Holt B, el Jarari L, Bertsch U, Salwender H, Zweegman S, Blau IW, Vellenga E, Weisel K, Pfreundschuh M, Jie KS, Neben K, van de Velde H, Duehrsen U, Schaafsma MR, Lindemann W, Kersten MJ, Peter N, Haenel M, Croockewit S, Martin H, Wittebol S, Bos GM, van Marwijk-Kooy M, Wijermans P, Goldschmidt H, Lokhorst HM: Bortezomib before and after autologous stem cell transplantation overcomes the negative prognostic impact of renal impairment in newly diagnosed multiple myeloma: a subgroup analysis from the HOVON-65/GMMG-HD4 trial. Haematologica 2014, 99(1):148-154.

Kongressbeiträge

Weisel K, Horger M, Goldschmidt H, Kanz L, Delorme S, Hillengass J: Whole-Body Reduced-Dose CT As Primary Staging and during Follow-up in First-Line Treatment of Transplant-Eligible Multiple Myeloma Patients: Results of the German GMMG-MM5 Trial. In.: American Society of Hematology Washington, DC; 2014.

Scheid C, Hielscher T, Bertsch U, Kunz C, Salwender H, Haenel M, Merz M, Mai EK, Hose D, Schurich B, Munder M, Schmidt-Wolf I, Gerecke C, Lindemann W, Zeis M, Weisel K, Duerig J, Jauch A, Goldschmidt H: Influence of Renal Impairment and Genetic Risk Factors on Response to Induction Therapy in the HD4 and MM5 Trials of the GMMG. In.: American Society of Hematology Washington, DC; 2014.

Merz M, Salwender H, Haenel M, Bertsch U, Kunz C, Hielscher T, Blau IW, Scheid C, Mai EK, Hose D, Schurich B, Munder M, Schmidt-Wolf IG, Gerecke C, Lindemann HW, Zeis M, Weisel K, Duerig J, Goldschmidt H: Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma–subgroup analysis from the GMMG-MM5 trial. In.: American Society of Hematology Washington, DC; 2014.

2013

Originalarbeiten

Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJ, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, Desai A, Cakana A, Liu K, van de Velde H, Esseltine DL, Moreau P: Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013, 31(26):3279-3287.

Broyl A, Kuiper R, van Duin M, van der Holt B, el Jarari L, Bertsch U, Zweegman S, Buijs A, Hose D, Lokhorst HM, Goldschmidt H, Sonneveld P: High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance. Blood 2013, 121(4):624-627.

Bøgsted M, Bilgrau AE, Wardell CP, Bertsch U, Schmitz A, Bødker JS, Kjeldsen MK, Goldschmidt H, Morgan GJ, Dybkaer K, Johnsen HE: Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma. PloS one 2013, 8(12):e83252.

Kongressbeiträge

Seckinger A, Meißner T, Bertsch U, Salwender H, Duerig J, Haenel M, Blau IW, Scheid C, Weisel K, Klein B, Goldschmidt H, Hose D: Bone turnover in multiple myeloma: impact of bortezomib-based induction therapy, high-dose melphalan, and lenalidomide consolidation on osteoblast and osteoclast function within the GMMG-MM5 Trial. In.: American Society of Hematology Washington, DC; 2013.

Moohialdin M, Salwender H, Bertsch U, Duerig J, Kunz C, Hielscher T, Zorn M, Haenel M, Blau IW, Hose D, Schurich B, Neben K, Seckinger A, Munder M, Lindemann W, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Goldschmidt H: Prognostic Value Of sFLC Ratio At Baseline On Response After Induction Therapy In Patients With Multiple Myeloma In The GMMG MM5 Trial. In.: American Society of Hematology Washington, DC; 2013.

2012

Originalarbeiten

Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GM, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM: Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012, 30(24):2946-2955.

Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, Duehrsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H: Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012, 119(4):940-948.

Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, el Jarari L, Mulligan G, Gregory W, Morgan G, Goldschmidt H, Lokhorst HM, van Duin M, Sonneveld P: A gene expression signature for high-risk multiple myeloma. Leukemia 2012, 26(11):2406-2413.

Kongressbeiträge

Goldschmidt H, Salwender H, Bertsch U, Hielscher T, Haenel M, Hose D, Jauch A, Duerig J, Blau I, Lindemann W, et al.: GMMG MM5 trial in newly diagnosed multiple myeloma to evaluate PAD vs. VCD induction prior to HDT followed by lenalidomide consolidation and maintenance- first interim analysis on induction. In: Haematologica: 2012. FERRATA STORTI FOUNDATION: 115-115.

2011

Originalarbeiten

van Duin M, Broyl A, de Knegt Y, Goldschmidt H, Richardson PG, Hop WC, van der Holt B, Joseph-Pietras D, Mulligan G, Neuwirth R, Sahota SS, Sonneveld P: Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica 2011, 96(11):1662-1669.

Johnson DC, Corthals SL, Walker BA, Ross FM, Gregory WM, Dickens NJ, Lokhorst HM, Goldschmidt H, Davies FE, Durie BG, Van Ness B, Child JA, Sonneveld P, Morgan GJ: Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011, 29(7):797-804.

Corthals SL, Kuiper R, Johnson DC, Sonneveld P, Hajek R, van der Holt B, Magrangeas F, Goldschmidt H, Morgan GJ, Avet-Loiseau H: Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients. Haematologica 2011, 96(11):1728-1732.

Kongressbeiträge

Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, Heiss C, van der Holt B, Schmitt S, Jarari Le, Salwender HJ, Blau IW, Pfreundschuh M, Weisel K, Duehrsen U, Lindemann W, Teschendorf C, Martin H, Scheid C, Haenel M, Derigs HG, Graeven U, Schmidt-Wolf IG, Peter N, Wattad M, Luntz S, Broyl A, Schubert J, Hoffmann M, Goerner M, Tischler J, Kaufmann M, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H: Combining information regarding chromosomal aberrations t (4; 14), Del (17p13) and the copy number of 1q21 with the International Staging System Classification Allows Stratification of Myeloma Patients Undergoing Autologous Stem Cell Transplantation: results from the HOVON-65/GMMG HD4 Trial. In.: American Society of Hematology; 2011.

2010

Originalarbeiten

Neben K, Jauch A, Bertsch U, Heiss C, Hielscher T, Seckinger A, Mors T, Mueller NZ, Hillengass J, Raab MS, Ho AD, Hose D, Goldschmidt H: Combining information regarding chromosomal aberrations t (4; 14) and del (17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation. Haematologica 2010, 95(7):1150-1157.

Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, Bertsch U, Buijs A, Stevens-Kroef M, Beverloo HB, Vellenga E, Zweegman S, Kersten MJ, van der Holt B, el Jarari L, Mulligan G, Goldschmidt H, van Duin M, Sonneveld P: Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010, 116(14):2543-2553.

Broyl A, Corthals SL, Jongen JL, van der Holt B, Kuiper R, de Knegt Y, van Duin M, el Jarari L, Bertsch U, Lokhorst HM, Durie BG, Goldschmidt H, Sonneveld P: Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. The Lancet Oncology 2010, 11(11):1057-1065.

Kongressbeiträge

Sonneveld P, Schmidt-Wolf I, van der Holt B, Jarari Le, Bertsch U, Salwender H, Zweegman S, Vellenga E, Schubert J, Blau IW, Jie A, Beverloo B, Hose D, Jauch A, van de Velde H, Schaafsma M, Lindemann W, Kersten MJ, Duehrsen U, Delforge M, Weisel K, Croockewit S, Martin H, Wittebol S, Scheid C, Bos G, van Marwijk-Kooy M, Wijermans P, Lokhorst H, Goldschmidt H: HOVON-65/GMMG-HD4 randomized phase III trial comparing bortezomib, doxorubicin, dexamethasone (PAD) vs VAD followed by high-dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). In.: American Society of Hematology; 2010.